$3.02
Value $243M
PLX and UNH stock compared: price, dividend, valuation and results, from SEC filings.
$3.02
Value $243M
$342.10
Value $311B
Protalix BioTherapeutics (PLX) has a market value of $243M and UnitedHealth (UNH) $311B. Over the last year, with dividends, PLX moved +60.6% and UNH +11.5%. The P/E is 11.8 for PLX and 19.6 for UNH. Dividend yield: PLX none, UNH 2.65%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
PLX$243M
UNH$311B
UNH is 1,276 times PLX
Revenue, 12 months
PLX$85M
UNH$450B
UNH is 5,309 times PLX
Net income, 12 months
PLX$21M
UNH$15.9B
UNH is 773 times PLX
Operating margin
PLX29.8%
UNH5.3%
24.5 points apart
ROIC
PLX31.3%
UNH11.3%
20.0 points apart
P/E
PLX11.8
UNH19.6
UNH is 1.7 times PLX
Dividend yield
PLX0.0%
UNH2.7%
2.7 points apart
5-year return
PLX+205.1%
UNH-17.0%
222.1 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
PLX+205.0%
UNH-17.0%
| Period | PLXWith dividends | UNHWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | +60.6%Price +60.6% | +11.5%Price +8.6% |
| 3 years since November 17, 2023 | +115.7%+29.2% a yearPrice +115.7% | -32.4%-12.2% a yearPrice -36.5% |
| 5 years since November 18, 2021 | +205.1%+25.0% a yearPrice +205.1% | -17.0%-3.7% a yearPrice -24.2% |
| 10 years since November 21, 2016 | -37.1%-4.5% a yearPrice -37.1% | +167.4%+10.3% a yearPrice +126.4% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
PLXProtalix BioTherapeuticsUNHUnitedHealth
| Price | $3.02 | $342.10 |
|---|---|---|
| Market value | $243M | $311B |
| Enterprise value (EV) | $221M | $356B |
| P/E | 11.8 | 19.6 |
| P/E, 5-year median | – | 25.0 |
| P/B | 3.0 | 3.0 |
| EV/EBIT | 8.8 | 14.9 |
| Free cash flow yield | 6.2% | 7.4% |
| Revenue, 12 months | $85M | $450B |
|---|---|---|
| Net income, 12 months | $21M | $15.9B |
| Free cash flow, 12 months | $15M | $22.8B |
| Earnings per share, 12 months | $0.25 | $17.52 |
| Revenue growth, year on year | -1.2% | 11.8% |
| Revenue growth a year, past | -3.5%over 5 years | +11.7%over 5 years |
| EPS growth a year, past | – | -3.8%over 5 years |
| Gross margin | 71.2% | 88.3% |
|---|---|---|
| Operating margin | 29.8% | 5.3% |
| Net margin | 24.3% | 3.5% |
| ROIC | 31.3% | 11.3% |
| ROE | 32.1% | 15.5% |
| Cash | $22M | $28.5B |
|---|---|---|
| Total debt | $9.1M | $74.3B |
| Net debt / EBITDA | -0.8 | 1.6 |
| Interest cover | – | 6.2× |
| Dividend yield | – | 2.7% |
|---|---|---|
| Dividend per share, 12 months | – | $9.06 |
| Dividend growth a year, past | – | +12.6%over 5 years |
| Buyback yield | – | 1.8% |
| Shareholder yield | – | 4.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, UnitedHealth ($311B) is about 1,276.1 times Protalix BioTherapeutics ($243M), at today's prices.
Since November 21, 2016, PLX's price moved -37.1% and UNH's +126.4%. With dividends: PLX -37.1% (-4.5% a year), UNH +167.4% (+10.3% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Protalix BioTherapeutics and 2.65% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.
At today's price, the P/E is 11.8 for PLX and 19.6 for UNH. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 24.3% for Protalix BioTherapeutics and 3.5% for UnitedHealth, and the operating margin 29.8% and 5.3%. Revenue was $85M and $450B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.